Objective: To study the clinicopathological characteristics of primary Non-Hodgkin's Lymphoma (NHL) of the prostate.
Methods: Two cases of primary NHL of the prostate were studied by analyzing the clinical data, pathological features, prognosis and review of the literature.
Results: HE showed that the normal prostatic tissues were replaced by diffuse-type cancer tissues composed of oval or round medium- to large- size lymphoid cells, with vesicular nuclei, fine chromatin, 2-4 membrane-bound nucleoli and scanty cytoplasm, with either amphophilic or basophilic. Immunohistochemistry revealed: CD20 +, CD79a +, CD10 -, CD5 -, CD3 - and CD45 - in Case 1 and CD20+ + +, PSA +/-, CKpan -, Syn -, CgA -, 34betaE12 -, P504S - and CD3 - in Case 2. Case 1 received chemotherapy combined with radiotherapy, relapsed 4 years later and stabilized by repeated chemotherapy. Case 2 experienced no recurrence after treated by chemotherapy.
Conclusion: Surgical treatment could be avoided by preoperative pathological diagnosis of primary NHL of the prostate, for which combined chemotherapy should be the first preference.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma.
Blood
January 2025
Tongji Hospital, Tongji University School of Medicine, Shanghai, China.
Prizloncabtagene autoleucel (prizlon-cel), a novel bispecific chimeric antigen receptor (CAR) T-cell, targets and eliminates CD19/CD20 positive tumor cells. This phase 1, open-label study investigated the safety and efficacy of prizlon-cel in patients with relapsed/refractory B-cell non-Hodgkin Lymphoma (r/r B-NHL). Patients with CD19 and/or CD20-positive r/r B-NHL received a 3-day lymphodepletion (cyclophosphamide: 300 mg/m2/d; fludarabine: 30 mg/m2/d) followed by an intravenous dose of prizlon-cel.
View Article and Find Full Text PDFPrimary Effusion Lymphoma Prognostic Score (PEL-PS): A Validated International Prognostic Score in HIV-Associated Primary Effusion Lymphoma.
Am J Hematol
January 2025
Biostatistics and Data Management Section, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Primary effusion lymphoma (PEL) is an HIV-associated B-cell non-Hodgkin lymphoma (NHL) caused by Kaposi sarcoma herpesvirus (KSHV). There is no validated prognostic model in PEL, and prognosis is thought to be poor compared to other HIV-associated NHL. We derived the PEL-Prognostic score (PEL-PS) from an international real-world training set of 59 patients with HIV-associated PEL who received first-line anthracycline-containing chemotherapy from the HIV and AIDS Malignancy Branch at the National Cancer Institute (NCI) in the United States and the National Center for HIV Malignancy at the Chelsea and Westminster Hospital (CWH) in England from 2000 to 2022.
View Article and Find Full Text PDFBilateral breast swelling in a pregnant woman with high-grade B-cell lymphoma, potentially Burkitt lymphoma.
Radiol Case Rep
March 2025
Breast Department, Hung Vuong Hospital, 128 Hong Bang Street, ward 12, district 5, Ho Chi Minh city, Vietnam.
Primary breast Burkitt lymphoma is an aggressive subtype of non-Hodgkin lymphoma (NHL) and extremely rare. Burkitt lymphoma involving both breasts during pregnancy was a rare condition with fifteen cases reported in literature. We present a case of a 19-year-old 36 weeks pregnant woman who came for a check-up due to bilateral breast swelling.
View Article and Find Full Text PDFPrimary breast Burkitt lymphoma with lactic acidosis in a child: a case report.
Turk J Pediatr
December 2024
Department of Pathology, Faculty of Medicine, Hacettepe University, Ankara, Türkiye.
Background: Primary breast lymphoma is extremely rare and constitutes approximately 1% of all non-Hodgkin's lymphomas (NHL). Only 1-5% of them are Burkitt type. We present a case of childhood primary breast Burkitt lymphoma (BL).
View Article and Find Full Text PDFHypothermia, Hallucinations, and Atrial Fibrillation Secondary to Diffuse Large B-cell Lymphoma.
Cureus
December 2024
Emergency Medicine, Northwell Health, Manhasset, USA.
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) in adults, constituting a significant portion of global incidence rates. DLBCL can be further classified via genetic expression profiling into molecular subsets consisting of not-otherwise specified (NOS) subset being the most prevalent, germinal center B-cell-like (GCB) subset, and activated B-cell-like (ABC) subset. The ABC subset, marked by abnormal NF-κB signaling, is associated with poorer outcomes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!